Publications

Title

Author

Year

IMPACT OF PNEUMOCOCCAL CONJUGATE VACCINE ON INVASIVE PNEUMOCOCCAL DISEASE IN THE GAMBIA: POPULATION-BASED SURVEILLANCE OVER 9 YEARS.

Mackenzie, G; Hill, P; JEFFRIES, D; Hossain, I; Ndiaye, M; Badji, H; Ikumapayi, U; Salaudeen, R; Jarju, S; Antonio, M; Ceesay, L; Sowe, D; Jasseh, M; Mulhollan, K; Knoll, M; Levine, O; Howie, S; Adegbola, R; GREENWOOD, B; Corrah, T;

2017

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, (2017).97 5

SAFETY AND IMMUNOGENICITY OF MONOVALENT AD26. ZEBOV AND MULTIVALENT MVA-BN-FILO HETEROLOGOUS PRIME-BOOST VACCINE REGIMENS AGAINST EBOLA IN AFRICAN HEALTHY ADULT VOLUNTEERS.

ANYWAINE, Z; Praygod, G; Anzala, O; Kalluvya, S; Kaleebu, P; Mutua, G; WHITWORTH, H; Luhn, K; Robinson, C; WATSON-JONES, D; Douoguih, M;

2017

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, (2017).97 5

Vaccination uptake and health service access amongst Polish and Romanian communitiesin England: a qualitative interview study – research summary.

BELL, S; Zatoński, M; MOUNIER-JACK, S;

2017

Journal of Health Inequalities, (2017).3 2 10.5114/jhi.2017.74213.

Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study.

Toh, ZQ; Russell, FM; Reyburn, R; Fong, J; Tuivaga, E; Ratu, T; Nguyen, CD; Devi, R; Kama, M; Matanitobua, S; Tabrizi, SN; Garland, SM; Sinha, R; Frazer, I; Tikoduadua, L; Kado, J; Rafai, E; MULHOLLAND, EK; Licciardi, PV;

2016

Clinical infectious diseases, (2016).64 7 10.1093/cid/ciw865.

Impact and Cost-effectiveness of Selective Human Papillomavirus Vaccination of Men Who Have Sex With Men.

Lin, A; Ong, KJ; Hobbelen, P; King, E; Mesher, D; EDMUNDS, WJ; Sonnenberg, P; Gilson, R; Bains, I; Choi, YH; TANTON, C; Soldan, K; JIT, M;

2016

Clinical infectious diseases, (2016).64 5 10.1093/cid/ciw845.

Real-time qPCR improves meningitis pathogen detection in invasive bacterial-vaccine preventable disease surveillance in Fiji.

Dunne, EM; Mantanitobua, S; Singh, SP; Reyburn, R; Tuivaga, E; Rafai, E; Tikoduadua, L; Porter, B; Satzke, C; Strachan, JE; Fox, KK; Jenkins, KM; Jenney, A; Baro, S; MULHOLLAND, EK; Kama, M; Russell, FM;

2016

Scientific reports, (2016).6 1 10.1038/srep39784.

Real-time dynamic modelling for the design of a cluster-randomized phase 3 Ebola vaccine trial in Sierra Leone.

CAMACHO, A; EGGO, RM; Goeyvaerts, N; Vandebosch, A; Mogg, R; FUNK, S; KUCHARSKI, AJ; WATSON, CH; Vangeneugden, T; EDMUNDS, WJ;

2016

Vaccine, (2016).35 4 10.1016/j.vaccine.2016.12.019.

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).

Henao-Restrepo, AM; CAMACHO, A; Longini, IM; WATSON, CH; EDMUNDS, WJ; Egger, M; Carroll, MW; Dean, NE; Diatta, I; Doumbia, M; Draguez, B; Duraffour, S; Enwere, G; Grais, R; Gunther, S; Gsell, P-S; Hossmann, S; Watle, SV; Kondé, MK; Kéïta, S; Kone, S; Kuisma, E; Levine, MM; Mandal, S; Mauget, T; ... Kieny, M-P.

2016

Lancet, (2016).389 10068 10.1016/S0140-6736(16)32621-6.

WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016.

Kobayashi, M; Schrag, SJ; Alderson, MR; Madhi, SA; Baker, CJ; Sobanjo-Ter Meulen, A; Kaslow, DC; SMITH, PG; Moorthy, VS; Vekemans, J;

2016

Vaccine, (2016).37 50 10.1016/j.vaccine.2016.12.029.

Japanese Media and the HPV Vaccine Saga.

LARSON, HJ;

2016

Clinical infectious diseases, (2016).64 4 10.1093/cid/ciw796.